CEO Kevin Conroy was paid $15,539,378 in fiscal year 2024, ↓ down 3.6% from fiscal year 2023, the 59th percentile of its disclosed peer group (SEC filing 0001124140-25-000034 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$15,539,378 ↓ Kevin Conroy total, FY2024 | 59th CEO pay percentile vs peers | 109:1 CEO-to-median pay ratio | 93.58% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Kevin Conroy | $1,083,368 | $0 | $13,496,138 | $0 | $712,329 | $0 | $247,543 | $15,539,378 |
| Chairman, President and Chief Executive Officer | ||||||||
| Aaron Bloomer | 431,868 | 600,000 | 6,002,837 | 0 | 136,662 | 0 | 15,421 | 7,186,788 |
| Executive Vice President and Chief Financial Officer | ||||||||
| Jacob Orville | 618,000 | 0 | 3,581,298 | 0 | 202,812 | 0 | 31,082 | 4,433,192 |
| Executive Vice President and General Manager, Screening | ||||||||
| Brian Baranick | 600,400 | 0 | 3,581,298 | 0 | 196,980 | 0 | 20,990 | 4,399,668 |
| Executive Vice President and General Manager, Precision Oncology | ||||||||
| Everett Cunningham | 315,503 | 0 | 3,820,428 | 0 | 0 | 0 | 5,723 | 4,141,654 |
| Former Executive Vice President and Former Chief Commercial Officer | ||||||||
| Jeffrey Elliott | 392,176 | 0 | 273,173 | 0 | 0 | 0 | 2,556,092 | 3,221,441 |
| Former Executive Vice President and Former Chief Financial Officer | ||||||||
| Sarah Condella | 509,000 | 0 | 1,910,213 | 0 | 167,344 | 0 | 58,998 | 2,645,555 |
| Executive Vice President, Human Resources | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Kevin Conroy | $15,539,378 | $16,119,899 | $14,223,999 | ↓ −580,521 |
| Aaron Bloomer | 7,186,788 | — | — | — |
| Jacob Orville | 4,433,192 | 3,668,331 | 2,749,179 | ↑ +764,861 |
| Brian Baranick | 4,399,668 | 3,574,009 | — | ↑ +825,659 |
| Everett Cunningham | 4,141,654 | 4,546,966 | 5,176,570 | ↓ −405,312 |
| Jeffrey Elliott | 3,221,441 | 4,077,681 | 3,870,737 | ↓ −856,240 |
| Sarah Condella | 2,645,555 | 3,058,696 | 2,714,543 | ↓ −413,141 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Exact Sciences's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper EXAS reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
The list of companies that name EXAS as a peer is temporarily unavailable — recheck shortly.
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2024 total |
|---|---|---|
| D. Scott Coward | Director | $333,892 |
| Daniel Levangie | Independent Director | $346,392 |
| Freda Lewis-Hall | Former director (through FY2024) | — |
| James Doyle | Lead Independent Director | $381,392 |
| Katherine Zanotti | Independent Director | $343,892 |
| Kathleen Sebelius | Former director (through FY2024) | $341,392 |
| Leslie Trigg | Independent Director | — |
| Michael Barber | Independent Director | $673,683 |
| Paul Clancy | Independent Director | $356,392 |
| Pierre Jacquet | Former director (through FY2024) | — |
| Shacey Petrovic | Independent Director | $338,892 |
| Timothy Scannell | Former director (through FY2024) | $111,364 |
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| D. Scott Coward | Director | 2025-06-12 | A | 5,398 | $0 | $0 | Common | Form 4 ↗ |
| Daniel Levangie | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2025-06-12 | A | 7,670 | 0 | 0 | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2025-06-12 | A | 9,994 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2025-06-12 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Paul Clancy | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-13 | D | 3,207 | 53 | 170,612 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 2,717 | 47 | 127,237 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 2,515 | 47 | 117,777 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-08-13 | D | 1,485 | 42 | 62,400 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-10-09 | D | 1,500 | 60 | 90,000 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-10-09 | D | 2,000 | 60 | 120,000 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-10-24 | D | 12,000 | 65 | 780,000 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-11-04 | D | 2,858 | 70 | 200,289 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-04 | D | 1,500 | 70 | 105,120 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-19 | D | 1,000 | 70 | 70,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-11-19 | D | 5,000 | 75 | 375,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 38,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 10,803 | 102 | 1,099,961 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 24,384 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 17,151 | 102 | 1,746,315 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 38,715 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,780 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2025-12-23 | — | 1,648 | — | — | 1 insider, 1 accrual row | ||
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,118 | 102 | 724,755 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 15,144 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 14,235 | 102 | 1,449,408 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 30,287 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 4,644 | 102 | 472,852 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 9,880 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,995 | 102 | 814,051 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 17,009 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,447 | 102 | 350,974 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,334 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 6,530 | 102 | 664,885 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 13,893 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,125 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 1,777 | 102 | 180,934 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 3,780 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 775 | 102 | 78,911 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 1,648 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 155,417 | 102 | 15,824,559 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 330,674 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 65,014 | 102 | 6,619,725 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 115,118 | 102 | 11,721,315 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 244,931 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 23,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 7,560 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 10,453 | 102 | 1,064,324 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,614 | 102 | 1,487,997 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 7,539 | 102 | 767,621 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,675 | 102 | 985,109 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 19,986 | 102 | 2,034,975 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 13,527 | 102 | 1,377,319 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 6,978 | 102 | 710,500 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 11,876 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 13,893 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,349 | 102 | 340,995 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 34,018 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 8,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,426 | 102 | 450,655 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,442 | 102 | 452,284 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 7,544 | 102 | 768,130 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 21,594 | 102 | 2,198,701 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 8,151 | 102 | 829,935 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 4,799 | 102 | 488,634 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 2,009 | 102 | 204,556 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,876 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,760 | 102 | 382,843 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,194 | 102 | 1,139,773 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 23,817 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,554 | 102 | 361,868 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 7,560 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 5,582 | 102 | 568,359 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 15,989 | 102 | 1,628,000 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 138,326 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 24,384 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | D | 14,938 | 102 | 1,517,551 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | A | 29,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 154,829 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | D | 6,196 | 103 | 640,976 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 13,181 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-02-25 | A | 20,321 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-02-25 | A | 38,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-25 | A | 23,224 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 3,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 1,913 | 103 | 197,766 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 27,786 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 18,143 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 13,060 | 103 | 1,348,445 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 10,419 | 103 | 1,075,762 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 8,528 | 103 | 880,516 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 18,143 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | A | 3,900 | 5 | 19,617 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 27,786 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 22,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 22,168 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 20,640 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 52,564 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 6,725 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 55,361 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,175 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 52,164 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 1,774 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | A | 53,323 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 154,829 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 83,360 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 18,143 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 100,916 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 34,110 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 235,388 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 86,750 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 46,538 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 29,061 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 191,891 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 4,395 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 417 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 138,679 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | A | 89,911 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 20,321 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 2,861 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 793 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 1,762 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 137,195 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | A | 33,321 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 3,244 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 16,406 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 12,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,694 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 38,707 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 23,224 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | A | 60,389 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 68,195 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 153,726 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 795 | — | — | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,422 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 13,925 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 7,790 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 11,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 21,948 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,368 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 9,656 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 44,336 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 66,047 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 117,427 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 1,397,738 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | A | 119,312 | 0 | 0 | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 10,786 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,738 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 7,095 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| D. Scott Coward | Director | 2025-06-12 | A | 5,398 | $0 | $0 | Common | Form 4 ↗ |
| Daniel Levangie | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Leslie Trigg | Director | 2025-06-12 | A | 7,670 | 0 | 0 | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2025-06-12 | A | 9,994 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2025-06-12 | A | 7,197 | 0 | 0 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Paul Clancy | Director | 2025-06-12 | A | 5,398 | 0 | 0 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-06-13 | D | 3,207 | 53 | 170,612 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | D | 2,717 | 47 | 127,237 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-08-05 | A | 5,350 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 5,350 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-08-05 | D | 2,515 | 47 | 117,777 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-08-13 | D | 1,485 | 42 | 62,400 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-10-09 | D | 1,500 | 60 | 90,000 | Common | Form 4 ↗ |
| James Doyle | Director | 2025-10-09 | D | 2,000 | 60 | 120,000 | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2025-10-24 | D | 12,000 | 65 | 780,000 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-11-04 | D | 2,858 | 70 | 200,289 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-04 | D | 1,500 | 70 | 105,120 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-11-19 | D | 1,000 | 70 | 70,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-11-19 | D | 5,000 | 75 | 375,000 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 38,715 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 10,803 | 102 | 1,099,961 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 24,384 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 17,151 | 102 | 1,746,315 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | A | 38,715 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,125 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,780 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 1,648 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,118 | 102 | 724,755 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 15,144 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 14,235 | 102 | 1,449,408 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 30,287 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 4,644 | 102 | 472,852 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 9,880 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,995 | 102 | 814,051 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 17,009 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,447 | 102 | 350,974 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,334 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 6,530 | 102 | 664,885 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 13,893 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 7,125 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 1,777 | 102 | 180,934 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 3,780 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 775 | 102 | 78,911 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | A | 1,648 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 155,417 | 102 | 15,824,559 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 330,674 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 65,014 | 102 | 6,619,725 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | D | 115,118 | 102 | 11,721,315 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 244,931 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 23,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 7,560 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 10,453 | 102 | 1,064,324 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,614 | 102 | 1,487,997 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 7,539 | 102 | 767,621 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 9,675 | 102 | 985,109 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 20,584 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 19,986 | 102 | 2,034,975 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 13,527 | 102 | 1,377,319 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 6,978 | 102 | 710,500 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 9,450 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 11,876 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 42,523 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 14,845 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 7,334 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 13,893 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2025-12-23 | D | 3,349 | 102 | 340,995 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 9,450 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 34,018 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 8,000 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 14,845 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 16,051 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,426 | 102 | 450,655 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 16,051 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 4,442 | 102 | 452,284 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2025-12-23 | D | 7,544 | 102 | 768,130 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 21,594 | 102 | 2,198,701 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 8,151 | 102 | 829,935 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | A | 28,779 | 0 | 0 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 4,799 | 102 | 488,634 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 2,009 | 102 | 204,556 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-23 | D | 28,779 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,876 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,955 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,760 | 102 | 382,843 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 11,194 | 102 | 1,139,773 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 23,817 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 3,554 | 102 | 361,868 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 7,560 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 1,859 | 102 | 189,283 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | A | 3,955 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 5,582 | 102 | 568,359 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2025-12-23 | D | 15,989 | 102 | 1,628,000 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2025-12-23 | A | 138,326 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2025-12-23 | D | 24,384 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | D | 14,938 | 102 | 1,517,551 | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2025-12-24 | A | 29,416 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 154,829 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | D | 6,196 | 103 | 640,976 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-25 | A | 13,181 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-02-25 | A | 20,321 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-02-25 | A | 38,707 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-02-25 | A | 28,063 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-25 | A | 23,224 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 3,900 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | D | 1,913 | 103 | 197,766 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 27,786 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 18,143 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 13,060 | 103 | 1,348,445 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 10,419 | 103 | 1,075,762 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 8,528 | 103 | 880,516 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 18,143 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-02-27 | A | 3,900 | 5 | 19,617 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 27,786 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | D | 22,168 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-02-27 | A | 22,168 | 0 | 0 | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Paul Clancy | Director | 2026-03-23 | D | 20,640 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| James Doyle | Director | 2026-03-23 | D | 52,564 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 6,725 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| Katherine Zanotti | Director | 2026-03-23 | D | 55,361 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,175 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 5,398 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 52,164 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 1,774 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | A | 53,323 | 0 | 0 | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 154,829 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 83,360 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 18,143 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 100,916 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 34,110 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 235,388 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 86,750 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 46,538 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 29,061 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,581 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 191,891 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 4,395 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 417 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 138,679 | — | — | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | A | 89,911 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 20,321 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 2,861 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 793 | — | — | Derivative, Class A Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 1,762 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 137,195 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | A | 33,321 | 0 | 0 | Common | Form 4 ↗ |
| Aaron Bloomer | EVP, Chief Financial Officer | 2026-03-23 | D | 28,063 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 3,244 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 16,406 | — | — | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 12,875 | — | — | Derivative, Class A Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 4,694 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 38,707 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 23,224 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | A | 60,389 | 0 | 0 | Common | Form 4 ↗ |
| James Herriott | SVP, General Counsel & Sec | 2026-03-23 | D | 68,195 | — | — | Common | Form 4 ↗ |
| Jacob Orville | EVP, GM, Screening | 2026-03-23 | D | 153,726 | — | — | Common | Form 4 ↗ |
| Brian Baranick | EVP, GM, Precision Oncology | 2026-03-23 | D | 795 | — | — | Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,422 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Leslie Trigg | Director | 2026-03-23 | D | 13,925 | — | — | Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 7,790 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 11,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 21,948 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Condella | EVP, Human Resources | 2026-03-23 | D | 6,368 | — | — | Common | Form 4 ↗ |
| Kimberly Popovits | Director | 2026-03-23 | D | 9,656 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 44,336 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 66,047 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 117,427 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | D | 1,397,738 | — | — | Common | Form 4 ↗ |
| Kevin Conroy | Director | 2026-03-23 | A | 119,312 | 0 | 0 | Common | Form 4 ↗ |
| D. Scott Coward | Director | 2026-03-23 | D | 10,786 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Michael Barber | Director | 2026-03-23 | D | 7,738 | — | — | Common | Form 4 ↗ |
| Shacey Petrovic | Director | 2026-03-23 | D | 7,095 | — | — | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Brian Baranick | PSU | 2024-02-26 | 1,237 | 19,792 | — | 44,533 | $1,249,469 |
| Sarah Condella | PSU | 2024-02-26 | 990 | 15,834 | — | 35,627 | 999,600 |
| Kevin Conroy | PSU | 2024-02-26 | 8,313 | 133,006 | — | 299,264 | 8,396,669 |
| Jacob Orville | PSU | 2024-02-26 | 1,237 | 19,792 | — | 44,533 | 1,249,469 |
| Jeffrey Elliott | RSU | 2024-02-26 | — | — | 4,750 | — | 273,173 |
| Aaron Bloomer | RSU | 2024-04-15 | — | — | 11,556 | — | 755,185 |
| Aaron Bloomer | RSU | 2024-04-15 | — | — | 51,619 | — | 3,373,302 |
| Sarah Condella | RSU | 2024-02-26 | — | — | 15,834 | — | 910,613 |
| Everett Cunningham | RSU | 2024-02-26 | — | — | 31,668 | — | 1,821,227 |
| Jacob Orville | RSU | 2024-02-26 | — | — | 19,793 | — | 1,138,295 |
| Aaron Bloomer | PSU | 2024-04-15 | 1,633 | 26,127 | — | 58,784 | 1,874,351 |
| Brian Baranick | RSU | 2024-02-26 | — | — | 19,793 | — | 1,138,295 |
| Brian Baranick | RSU | 2024-08-05 | — | — | 21,401 | — | 1,193,534 |
| Kevin Conroy | RSU | 2024-02-26 | — | — | 88,671 | — | 5,099,469 |
| Everett Cunningham | PSU | 2024-02-26 | 1,979 | 31,668 | — | 71,253 | 1,999,201 |
| Jacob Orville | RSU | 2024-08-05 | — | — | 21,401 | — | 1,193,534 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Brian Baranick | $2,331,829 | $1,249,469 | $0 | 34.9% |
| Sarah Condella | 910,613 | 999,600 | 0 | 52.3% |
| Kevin Conroy | 5,099,469 | 8,396,669 | 0 | 62.2% |
| Jacob Orville | 2,331,829 | 1,249,469 | 0 | 34.9% |
| Jeffrey Elliott | 273,173 | 0 | 0 | 0.0% |
| Aaron Bloomer | 4,128,487 | 1,874,351 | 0 | 31.2% |
| Everett Cunningham | 1,821,227 | 1,999,201 | 0 | 52.3% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kevin Conroy | RSU | 54,429 | — | $3,058,366 |
| Brian Baranick | RSU | 44,533 | — | 2,502,309 |
| Sarah Condella | RSU | 35,627 | — | 2,001,881 |
| Jacob Orville | RSU | 2,248 | — | 126,315 |
| Sarah Condella | RSU | 15,834 | — | 889,712 |
| Kevin Conroy | Option | 66,047 | 44.37 | — |
| Brian Baranick | RSU | 21,401 | — | 1,202,522 |
| Sarah Condella | Option | 6,581 | 98.18 | — |
| Jacob Orville | Option | 6,581 | 98.18 | — |
| Brian Baranick | RSU | 1,729 | — | 97,153 |
| Jacob Orville | RSU | 44,533 | — | 2,502,309 |
| Kevin Conroy | RSU | 26,361 | — | 1,481,225 |
| Jacob Orville | RSU | 19,793 | — | 1,112,169 |
| Kevin Conroy | RSU | 299,264 | — | 16,815,644 |
| Kevin Conroy | Option | 34,110 | 92.62 | — |
| Sarah Condella | Option | 7,790 | 92.62 | — |
| Kevin Conroy | RSU | 244,931 | — | 13,762,673 |
| Sarah Condella | Option | 11,700 | 44.37 | — |
| Kevin Conroy | RSU | 88,671 | — | 4,982,423 |
| Aaron Bloomer | RSU | 58,784 | — | 3,303,073 |
| Aaron Bloomer | RSU | 51,619 | — | 2,900,472 |
| Jacob Orville | RSU | 42,523 | — | 2,389,367 |
| Brian Baranick | RSU | 42,523 | — | 2,389,367 |
| Sarah Condella | RSU | 7,909 | — | 444,407 |
| Sarah Condella | RSU | 34,018 | — | 1,911,471 |
| Jacob Orville | RSU | 21,401 | — | 1,202,522 |
| Brian Baranick | RSU | 19,793 | — | 1,112,169 |
| Jacob Orville | RSU | 14,175 | — | 796,493 |
| Brian Baranick | RSU | 14,175 | — | 796,493 |
| Aaron Bloomer | RSU | 11,556 | — | 649,332 |
| Kevin Conroy | Option | 235,388 | 21.68 | — |
| Sarah Condella | RSU | 11,340 | — | 637,195 |
| Kevin Conroy | RSU | 10,374 | — | 582,915 |
| Jacob Orville | RSU | 7,909 | — | 444,407 |
| Brian Baranick | RSU | 7,909 | — | 444,407 |
| Jeffrey Elliott | Option | 11,361 | 92.62 | — |
| Jeffrey Elliott | Option | 12,875 | 98.18 | — |
| Sarah Condella | RSU | 2,248 | — | 126,315 |
| Sarah Condella | Option | 21,948 | 21.68 | — |
| Kevin Conroy | Option | 66,723 | 23.38 | — |
| Kevin Conroy | Option | 100,916 | 98.18 | — |
| Sarah Condella | Option | 3,900 | 5.03 | — |
The compensation program is designed to attract, motivate, and retain qualified executives by aligning their interests with long-term shareholder value creation. It emphasizes a pay-for-performance philosophy where a significant portion of compensation is variable and at-risk, tied to rigorous financial and operational performance targets and stock price performance.
| CEO STI target (% of salary) | 140% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-12 | 140,371,292 | 9,625,458 | 441,070 | 93.58% | Passed |
| 2024 | 2024-06-13 | 131,505,677 | 12,170,551 | 284,279 | 91.53% | Passed |
| 2023 | 2023-06-08 | 125,242,817 | 12,934,948 | 407,218 | 90.64% | Passed |
| 2022 | 2022-06-09 | 127,608,500 | 8,862,911 | 304,680 | 93.51% | Passed |
| 2021 | 2021-06-30 | 87,736,328 | 42,105,148 | 374,051 | 67.57% | Passed |
| 2020 | 2020-07-23 | 103,318,594 | 3,994,544 | 697,884 | 96.28% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2025 | 2025-06-12 | 93.58%a |
| 2024 | 2024-06-13 | 91.53%b |
| 2023 | 2023-06-08 | 90.64%c |
a. Approved under the standard stated in the filing — “Abstentions will therefor have no effect on Proposal 1.”.
b. Approved under the standard stated in the filing — “Broker non-votes and abstentions are not counted as votes cast on any proposal considered at the Annual Meeting and, therefore, will have no effect on Proposals 1 and 3.”.
c. Approved under the standard stated in the filing — “Broker non-votes and abstentions are not counted as votes cast on any proposal considered at the Annual Meeting and, therefore, will have no effect on Proposals 1, 3, 4, and 6.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 109 : 1 |
|---|---|
| CEO total compensation | $15,539,378 |
| Median employee compensation | $142,608 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael BarberIndependent · Audit and Finance · Innovation, Technology & Pipeline (Chair) · Newly elected | $102,500 | $571,183 | — | — | — | $673,683 |
| James DoyleIndependent · Lead Independent Director · Corporate Governance and Nominating · Human Capital | 127,500 | 253,892 | — | — | — | 381,392 |
| Paul ClancyIndependent · Audit and Finance (Chair) · Corporate Governance and Nominating | 102,500 | 253,892 | — | — | — | 356,392 |
| Daniel LevangieIndependent · Audit and Finance · Human Capital | 92,500 | 253,892 | — | — | — | 346,392 |
| Katherine ZanottiIndependent · Human Capital (Chair) | 90,000 | 253,892 | — | — | — | 343,892 |
| Kathleen SebeliusIndependent · Departed during FY | 87,500 | 253,892 | — | — | — | 341,392 |
| Shacey PetrovicIndependent · Corporate Governance and Nominating (Chair) | 85,000 | 253,892 | — | — | — | 338,892 |
| D. Scott CowardEmployee director · Innovation, Technology & Pipeline | 80,000 | 253,892 | — | — | — | 333,892 |
| Timothy ScannellIndependent · Not standing for re-election · Departed during FY | 0 | 111,364 | — | — | — | 111,364 |
| Freda Lewis-HallIndependent · Human Capital · Not standing for re-election · Departed during FY | 0 | 0 | — | — | — | 0 |
| Kimberly PopovitsIndependent · Human Capital · Innovation, Technology & Pipeline | 0 | 0 | — | — | — | 0 |
| Kevin ConroyEmployee director · Board Chair | — | — | — | — | — | 0 |
| Leslie TriggIndependent · Newly elected | 0 | 0 | — | — | — | 0 |
| Pierre JacquetIndependent · Not standing for re-election · Departed during FY | 0 | 0 | — | — | — | 0 |
| Annual cash retainer | $70,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 12,500 / 20,000 / 15,000 |
| Stock ownership guideline | $5 |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $767,500 |
| Equity awards (grant-date value) | $2,459,791 |
| All other compensation | $0 |
| Total cost of the board | $3,227,291 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Exact Sciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Exact Sciences.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Seagen, Inc. | 2022 | David Epstein | $190,385 | $14,815,386 | $42,381,246 | $0 | $57,460,546 |
| 2 | Incyte Corporation | 2025 | William Meury | 647,260 | 27,509,657 | 2,573,998 | 1,300,000 | 32,085,952 |
| 3 | BioMarin Pharmaceutical Inc. | 2025 | Alexander Hardy | 1,130,769 | 16,833,629 | 1,909,310 | 1,644,500 | 21,927,563 |
| 4 | Horizon Therapeutics Public Ltd Co | 2022 | Timothy Walbert | 1,292,727 | 16,601,305 | 0 | 0 | 20,103,869 |
| 5 | Masimo Corporation | 2025 | Catherine Szyman | 850,048 | 16,388,693 | 1,399,998 | 1,130,000 | 19,797,140 |
| 6 | Align Technology, Inc. | 2025 | Joseph Hogan | 1,400,000 | 16,556,872 | 0 | 1,220,100 | 19,193,988 |
| 7 | Insulet Corporation | 2025 | Ashley McEvoy | 729,808 | 12,958,850 | 2,999,913 | 2,031,562 | 18,858,968 |
| 8 | Edwards Lifesciences Corporation | 2025 | Bernard Zovighian | 1,192,500 | 7,167,024 | 6,499,109 | 2,406,537 | 17,454,255 |
| 9 | ResMed Inc. | 2026 | Michael Farrell | 1,272,895 | 9,749,468 | 3,249,907 | 1,738,857 | 16,201,649 |
| 10 | Hologic, Inc. | 2024 | Stephen MacMillan | 1,212,628 | 9,141,468 | 2,937,477 | 1,990,413 | 15,819,261 |
| 11 | Exact Sciences | 2024 | Kevin Conroy | 1,083,368 | 13,496,138 | 0 | 712,329 | 15,539,378 |
| 12 | Natera, Inc. | 2025 | Steven Chapman | 853,710 | 12,979,558 | 0 | 1,114,151 | 14,957,319 |
| 13 | Alnylam Pharmaceuticals, Inc. | 2025 | Yvonne Greenstreet | 1,404,200 | 5,512,500 | 4,363,380 | 3,562,500 | 14,867,600 |
| 14 | IDEXX Laboratories, Inc. | 2025 | Jonathan Mazelsky | 1,150,000 | 5,399,881 | 5,400,001 | 2,593,000 | 14,580,122 |
| 15 | Agilent Technologies, Inc. | 2025 | Padraig McDonnell | 1,141,345 | 8,169,850 | 2,017,759 | 1,436,809 | 12,827,236 |
| 16 | Quidel Corporation | 2025 | Brian Blaser | 1,000,000 | 8,965,822 | 0 | 1,274,500 | 11,255,782 |
| 17 | Illumina, Inc. | 2025 | Jacob Thaysen | 1,000,000 | 8,763,122 | 0 | 1,155,000 | 11,018,895 |
| 18 | Guardant Health, Inc. | 2025 | AmirAli Talasaz | 1 | 8,647,709 | 0 | 0 | 8,661,227 |
| 19 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 20 | Bio-Rad Laboratories, Inc. | 2025 | Norman Schwartz | 1,089,877 | 4,856,574 | 1,458,975 | 562,088 | 7,995,841 |
| 21 | DexCom, Inc. | 2025 | Jacob Leach | 768,962 | 5,936,062 | 0 | 1,164,780 | 7,985,960 |
| 22 | 10x Genomics, Inc. | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 23 | Penumbra, Inc. | 2025 | Adam Elsesser | 850,000 | 0 | 0 | 0 | 851,621 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Exact Sciences | 47% | PSU 60 · RSU 40 | No | Aon |
| 10x Genomics, Inc. | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Agilent Technologies, Inc. | not disclosed | PSU 60 · Options 20 · RSU 20 | No | Semler Brossy |
| Align Technology, Inc. | 58.1% | MSU 70 · RSU 30 | Yes — Relative Total Stockholder Return (TSR) vs. Nasdaq Composite Index | Compensia, Inc. |
| Alnylam Pharmaceuticals, Inc. | 200% | PSU 50 · RSU 25 · Option 25 | No | Pay Governance |
| Bio-Rad Laboratories, Inc. | not disclosed | not disclosed | not disclosed | Compensia, Inc. |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| BioMarin Pharmaceutical Inc. | 130% | PSU 66 · RSU 21 · Options 13 | Yes — Relative TSR | Aon Human Capital Solutions |
| DexCom, Inc. | not disclosed | not disclosed | Yes — Relative TSR Performance Metric | Aon Hewitt Consulting Company |
| Edwards Lifesciences Corporation | 127% | Options 50 · PSU 25 · RSU 25 | No | Semler Brossy Consulting Group |
| Guardant Health, Inc. | 140% | PSU 50 · RSU 50 | No | Aon |
| Hologic, Inc. | 109% | PSU 50 · RSU 25 · Option 25 | No | Pearl Meyer & Partners, LLC |
| Horizon Therapeutics Public Ltd Co | 100% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon |
| IDEXX Laboratories, Inc. | 140% | Options 50 · PSU 50 | No | Farient |
| Illumina, Inc. | 1155% | not disclosed | Yes — 3-year rTSR performance against select companies in the Nasdaq Biotechnology Index | Aon (Aon's Human Capital Practice, a division of Aon, plc) |
| Incyte Corporation | 138.6% | Performance Shares 60 · RSU 40 | Yes — relative total shareholder return (TSR) | Aon |
| Insulet Corporation | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| Masimo Corporation | not disclosed | not disclosed | not disclosed | FW Cook |
| Natera, Inc. | 131.1% | PSU 50 · RSU 50 | No | Aon |
| Penumbra, Inc. | not disclosed | not disclosed | No | Compensia |
| Quidel Corporation | 127% | PSU 60 · RSU 40 | Yes — Total Shareholder Return (TSR) | Compensia |
| ResMed Inc. | not disclosed | PSU 50 · RSU 25 · Options 25 | Yes — Relative TSR | FW Cook |
| Seagen, Inc. | 130% | RSU 60 · PSU 40 | Yes — Relative TSR | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Kevin Conroy | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation”. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 2 | Section 01, Aaron Bloomer | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation”. As printed: 7,186,788. Filing ↗machine: span 1088764–1088773 |
| 3 | Section 01, Jacob Orville | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation”. As printed: 4,433,192. Filing ↗machine: span 1105395–1105404 |
| 4 | Section 01, Brian Baranick | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation”. As printed: 4,399,668. Filing ↗machine: span 1114796–1114805 |
| 5 | Section 01, Everett Cunningham | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation”. As printed: 4,141,654. Filing ↗machine: span 1132827–1132836 |
| 6 | Section 01, Jeffrey Elliott | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation”. As printed: 3,221,441. Filing ↗machine: span 1094888–1094897 |
| 7 | Section 01, Sarah Condella | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation”. As printed: 2,645,555. Filing ↗machine: span 1123056–1123065 |
| 8 | Section 03, Brian Baranick PSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1212305–1212314 |
| 9 | Section 03, Sarah Condella PSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1223017–1223024 |
| 10 | Section 03, Kevin Conroy PSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1165648–1165657 |
| 11 | Section 03, Jacob Orville PSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1198548–1198557 |
| 12 | Section 03, Jeffrey Elliott RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Grants of Plan-Based Awards in 2024” · grants of plan-based awards table. Filing ↗machine: t209 · r10 · c18 · span 1185620–1185627 |
| 13 | Section 03, Aaron Bloomer RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1175907–1175914 |
| 14 | Section 03, Aaron Bloomer RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1172765–1172774 |
| 15 | Section 03, Sarah Condella RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1219876–1219883 |
| 16 | Section 03, Everett Cunningham RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1230581–1230590 |
| 17 | Section 03, Jacob Orville RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1192712–1192721 |
| 18 | Section 03, Aaron Bloomer PSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1178599–1178608 |
| 19 | Section 03, Brian Baranick RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1205569–1205578 |
| 20 | Section 03, Brian Baranick RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1209186–1209195 |
| 21 | Section 03, Kevin Conroy RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1162444–1162453 |
| 22 | Section 03, Everett Cunningham PSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1233726–1233735 |
| 23 | Section 03, Jacob Orville RSU | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Executive Compensation” · grants of plan-based awards table. Filing ↗machine: span 1195854–1195863 |
| 24 | Section 07, pay ratio | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “CEO Pay Ratio”. As printed: 109 : 1. Filing ↗ |
| 25 | Section 08, Michael Barber | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 673,683. Filing ↗machine: span 600556–600807 |
| 26 | Section 08, James Doyle | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 381,392. Filing ↗machine: span 606269–606706 |
| 27 | Section 08, Paul Clancy | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 356,392. Filing ↗machine: span 602334–602771 |
| 28 | Section 08, Daniel Levangie | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 346,392. Filing ↗machine: span 610390–610827 |
| 29 | Section 08, Katherine Zanotti | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 343,892. Filing ↗machine: span 623524–624048 |
| 30 | Section 08, Kathleen Sebelius | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 341,392. Filing ↗machine: span 619142–619579 |
| 31 | Section 08, Shacey Petrovic | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 338,892. Filing ↗machine: span 614513–614950 |
| 32 | Section 08, D. Scott Coward | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 333,892. Filing ↗machine: span 604303–604740 |
| 33 | Section 08, Timothy Scannell | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 111,364. Filing ↗machine: span 615994–616535 |
| 34 | Section 08, Freda Lewis-Hall | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 35 | Section 08, Kimberly Popovits | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 36 | Section 08, Kevin Conroy | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 37 | Section 08, Leslie Trigg | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 38 | Section 08, Pierre Jacquet | DEF 14A | 2025-04-29 | 0001124140-25-000034 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 39 | Section 02, D. Scott Coward 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086883 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Daniel Levangie 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086884 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Shacey Petrovic 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086886 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Leslie Trigg 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086887 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Kimberly Popovits 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086888 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Michael Barber 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086890 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, James Doyle 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086891 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Katherine Zanotti 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Paul Clancy 2025-06-12 | Form 4 | 2025-06-16 | 0000950170-25-086889 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Katherine Zanotti 2025-06-13 | Form 4 | 2025-06-16 | 0000950170-25-086885 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Brian Baranick 2025-08-05 | Form 4 | 2025-08-07 | 0000950170-25-105255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Brian Baranick 2025-08-05 | Form 4 | 2025-08-07 | 0000950170-25-105255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Jacob Orville 2025-08-05 | Form 4 | 2025-08-07 | 0000950170-25-105256 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Brian Baranick 2025-08-05 | Form 4 | 2025-08-07 | 0000950170-25-105255 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Jacob Orville 2025-08-05 | Form 4 | 2025-08-07 | 0000950170-25-105256 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Jacob Orville 2025-08-05 | Form 4 | 2025-08-07 | 0000950170-25-105256 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, James Doyle 2025-08-13 | Form 4 | 2025-08-14 | 0000950170-25-108967 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, James Herriott 2025-10-09 | Form 4 | 2025-10-10 | 0001193125-25-237239 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, James Doyle 2025-10-09 | Form 4 | 2025-10-10 | 0001193125-25-237233 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Katherine Zanotti 2025-10-24 | Form 4 | 2025-10-27 | 0001193125-25-251958 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Brian Baranick 2025-11-04 | Form 4 | 2025-11-06 | 0001193125-25-270166 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, James Herriott 2025-11-04 | Form 4 | 2025-11-06 | 0001193125-25-270168 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, James Herriott 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291649 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, Jacob Orville 2025-11-19 | Form 4 | 2025-11-21 | 0001193125-25-291651 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Aaron Bloomer 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Aaron Bloomer 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Aaron Bloomer 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Aaron Bloomer 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Aaron Bloomer 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Kevin Conroy 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Kevin Conroy 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Kevin Conroy 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Kevin Conroy 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Kevin Conroy 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 103 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 104 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 105 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 106 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 107 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 108 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 109 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 110 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 111 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 112 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 113 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 114 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 115 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 116 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 117 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 118 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 119 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 120 | Section 02, James Herriott 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337152 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 121 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 122 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 123 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 124 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 125 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 126 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 127 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 128 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 129 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 130 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 131 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 132 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 133 | Section 02, Jacob Orville 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337156 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 134 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 135 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 136 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 137 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 138 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 139 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 140 | Section 02, Brian Baranick 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 141 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 142 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 143 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 144 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 145 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 146 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 147 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 148 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 149 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 150 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 151 | Section 02, Sarah Condella 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337154 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 152 | Section 02, Kevin Conroy 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337153 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 153 | Section 02, Aaron Bloomer 2025-12-23 | Form 4 | 2025-12-30 | 0001193125-25-337151 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 154 | Section 02, Brian Baranick 2025-12-24 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 155 | Section 02, Brian Baranick 2025-12-24 | Form 4 | 2025-12-30 | 0001193125-25-337155 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 156 | Section 02, Aaron Bloomer 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082834 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 157 | Section 02, Kevin Conroy 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082828 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 158 | Section 02, Kevin Conroy 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082828 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 159 | Section 02, Kevin Conroy 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082828 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 160 | Section 02, James Herriott 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082829 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 161 | Section 02, Jacob Orville 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082839 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 162 | Section 02, Brian Baranick 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082836 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 163 | Section 02, Sarah Condella 2026-02-25 | Form 4 | 2026-02-27 | 0001193125-26-082832 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 164 | Section 02, Sarah Condella 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 165 | Section 02, Sarah Condella 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 166 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 167 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 168 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 169 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 170 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 171 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 172 | Section 02, Sarah Condella 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089302 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 173 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 174 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 175 | Section 02, Kevin Conroy 2026-02-27 | Form 4 | 2026-03-03 | 0001193125-26-089303 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 176 | Section 02, Michael Barber 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118742 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 177 | Section 02, Paul Clancy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118743 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 178 | Section 02, Paul Clancy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118743 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 179 | Section 02, James Doyle 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118744 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 180 | Section 02, James Doyle 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118744 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 181 | Section 02, Kimberly Popovits 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118745 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 182 | Section 02, Katherine Zanotti 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118747 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 183 | Section 02, Katherine Zanotti 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118747 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 184 | Section 02, Shacey Petrovic 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118748 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 185 | Section 02, D. Scott Coward 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 186 | Section 02, D. Scott Coward 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 187 | Section 02, D. Scott Coward 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 188 | Section 02, Jacob Orville 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 189 | Section 02, Jacob Orville 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 190 | Section 02, Jacob Orville 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 191 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 192 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 193 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 194 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 195 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 196 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 197 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 198 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 199 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 200 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 201 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 202 | Section 02, Aaron Bloomer 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 203 | Section 02, Aaron Bloomer 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 204 | Section 02, Aaron Bloomer 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 205 | Section 02, Aaron Bloomer 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 206 | Section 02, James Herriott 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 207 | Section 02, James Herriott 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 208 | Section 02, James Herriott 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 209 | Section 02, James Herriott 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 210 | Section 02, Brian Baranick 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 211 | Section 02, Brian Baranick 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 212 | Section 02, Brian Baranick 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 213 | Section 02, Aaron Bloomer 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118759 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 214 | Section 02, Leslie Trigg 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 215 | Section 02, Shacey Petrovic 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118748 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 216 | Section 02, D. Scott Coward 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 217 | Section 02, D. Scott Coward 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 218 | Section 02, Jacob Orville 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 219 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 220 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 221 | Section 02, James Herriott 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118762 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 222 | Section 02, Jacob Orville 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118754 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 223 | Section 02, Brian Baranick 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118765 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 224 | Section 02, Michael Barber 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118742 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 225 | Section 02, Leslie Trigg 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118740 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 226 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 227 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 228 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 229 | Section 02, Sarah Condella 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118758 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 230 | Section 02, Kimberly Popovits 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118745 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 231 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 232 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 233 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 234 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 235 | Section 02, Kevin Conroy 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118755 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 236 | Section 02, D. Scott Coward 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118752 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 237 | Section 02, Michael Barber 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118742 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 238 | Section 02, Shacey Petrovic 2026-03-23 | Form 4 | 2026-03-23 | 0001193125-26-118748 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 239 | Section 06, 2025 vote | Form 8-K | 2025-06-16 | 0001124140-25-000046 | Item 5.07 · say-on-pay result. As reported: 93.58% (votes for as printed: 140,371,292). Filing ↗ |
| 240 | Section 06, 2024 vote | Form 8-K | 2024-06-17 | 0001124140-24-000054 | Item 5.07 · say-on-pay result. As reported: 91.53% (votes for as printed: 131,505,677). Filing ↗ |
| 241 | Section 06, 2023 vote | Form 8-K | 2023-06-12 | 0001124140-23-000054 | Item 5.07 · say-on-pay result. As reported: 90.64% (votes for as printed: 125,242,817). Filing ↗ |
| 242 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 243 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 244 | Section 09b board cost (computed) | Computed | — | — | Cash 767,500 + equity 2,459,791 + all other 0 = 3,227,291, summed across the director compensation table rows.machine: formula: Σ = 3,227,291 |
| 245 | Seagen, Inc., Section 10b CEO total | DEF 14A | 2023-04-18 | 0001060736-23-000019 | CEO total compensation as printed in Seagen, Inc.'s own proxy. As printed: 57,460,546. Filing ↗machine: r2 · c36 · span 1339226–1339236 |
| 246 | Incyte Corporation, Section 10b CEO total | DEF 14A | 2026-04-28 | 0000879169-26-000031 | CEO total compensation as printed in Incyte Corporation's own proxy. As printed: 32,085,952. Filing ↗machine: t91 · r2 · c16 · span 637817–637827 |
| 247 | BioMarin Pharmaceutical Inc., Section 10b CEO total | DEF 14A | 2026-04-21 | 0001628280-26-026290 | CEO total compensation as printed in BioMarin Pharmaceutical Inc.'s own proxy. As printed: 21,927,563. Filing ↗machine: span 1384905–1384915 |
| 248 | Horizon Therapeutics Public Ltd Co, Section 10b CEO total | DEF 14A | 2023-06-30 | 0001193125-23-180318 | CEO total compensation as printed in Horizon Therapeutics Public Ltd Co's own proxy. As printed: 20,103,869. Filing ↗machine: span 746414–746424 |
| 249 | Masimo Corporation, Section 10b CEO total | 10-K | 2026-05-01 | 0001104659-26-054180 | CEO total compensation as printed in Masimo Corporation's own proxy. As printed: 19,797,140. Filing ↗machine: r4 · c22 · span 477159–477169 |
| 250 | Align Technology, Inc., Section 10b CEO total | DEF 14A | 2026-04-07 | 0001097149-26-000023 | CEO total compensation as printed in Align Technology, Inc.'s own proxy. As printed: 19,193,988. Filing ↗machine: r2 · c42 · span 933168–933178 |
| 251 | Insulet Corporation, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001140361-26-013333 | CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. Filing ↗machine: t218 · r3 · c25 · span 1028076–1028087 |
| 252 | Edwards Lifesciences Corporation, Section 10b CEO total | DEF 14A | 2026-03-26 | 0001099800-26-000015 | CEO total compensation as printed in Edwards Lifesciences Corporation's own proxy. As printed: 17,454,255. Filing ↗machine: r2 · c27 · span 965441–965451 |
| 253 | ResMed Inc., Section 10b CEO total | DEF 14A | 2026-10-01 | 0000943819-26-000080 | CEO total compensation as printed in ResMed Inc.'s own proxy. As printed: 16,201,649. Filing ↗machine: span 1267106–1267116 |
| 254 | Hologic, Inc., Section 10b CEO total | DEF 14A | 2025-01-16 | 0001140361-25-001287 | CEO total compensation as printed in Hologic, Inc.'s own proxy. As printed: 15,819,261. Filing ↗machine: r2 · c25 · span 1549664–1549674 |
| 255 | Exact Sciences (subject), Section 10b CEO total | DEF 14A | 2025-04-29 | 0001124140-25-000034 | CEO total compensation as printed in Exact Sciences's own proxy. As printed: 15,539,378. Filing ↗machine: span 1077855–1077865 |
| 256 | Natera, Inc., Section 10b CEO total | DEF 14A | 2026-04-23 | 0001104659-26-047770 | CEO total compensation as printed in Natera, Inc.'s own proxy. As printed: 14,957,319. Filing ↗machine: t190 · r5 · c14 · span 1269868–1269878 |
| 257 | Alnylam Pharmaceuticals, Inc., Section 10b CEO total | DEF 14A | 2026-04-06 | 0001628280-26-023923 | CEO total compensation as printed in Alnylam Pharmaceuticals, Inc.'s own proxy. As printed: 14,867,600. Filing ↗machine: span 1294691–1294701 |
| 258 | IDEXX Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-27 | 0000874716-26-000064 | CEO total compensation as printed in IDEXX Laboratories, Inc.'s own proxy. As printed: 14,580,122. Filing ↗machine: span 1576008–1576018 |
| 259 | Agilent Technologies, Inc., Section 10b CEO total | DEF 14A | 2026-02-06 | 0001193125-26-040286 | CEO total compensation as printed in Agilent Technologies, Inc.'s own proxy. As printed: 12,827,236. Filing ↗machine: r3 · c29 · span 1450982–1450992 |
| 260 | Quidel Corporation, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001906324-26-000018 | CEO total compensation as printed in Quidel Corporation's own proxy. As printed: 11,255,782. Filing ↗machine: r4 · c24 · span 760612–760622 |
| 261 | Illumina, Inc., Section 10b CEO total | DEF 14A | 2026-04-09 | 0001193125-26-149669 | CEO total compensation as printed in Illumina, Inc.'s own proxy. As printed: 11,018,895. Filing ↗machine: r4 · c14 · span 728526–728536 |
| 262 | Guardant Health, Inc., Section 10b CEO total | DEF 14A | 2026-04-28 | 0001193125-26-187403 | CEO total compensation as printed in Guardant Health, Inc.'s own proxy. As printed: 8,661,227. Filing ↗machine: r7 · c31 · span 773149–773158 |
| 263 | Bio-Techne Corporation, Section 10b CEO total | DEF 14A | 2025-09-19 | 0001308179-25-000599 | CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. Filing ↗machine: span 792074–792083 |
| 264 | Bio-Rad Laboratories, Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0000012208-26-000020 | CEO total compensation as printed in Bio-Rad Laboratories, Inc.'s own proxy. As printed: 7,995,841. Filing ↗machine: r2 · c24 · span 654200–654209 |
| 265 | DexCom, Inc., Section 10b CEO total | DEF 14A | 2026-04-15 | 0001093557-26-000061 | CEO total compensation as printed in DexCom, Inc.'s own proxy. As printed: 7,985,960. Filing ↗machine: span 940364–940373 |
| 266 | 10x Genomics, Inc., Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics, Inc.'s own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 267 | Penumbra, Inc., Section 10b CEO total | DEF 14A | 2026-04-29 | 0001321732-26-000010 | CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. Filing ↗machine: span 424797–424804 |
| 268 | Section 10a, Edwards Lifesciences Corporation reciprocity | DEF 14A | — | 0001099800-26-000015 | Edwards Lifesciences Corporation's most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 269 | Section 10a, Seagen, Inc. reciprocity | DEF 14A | — | 0001060736-23-000019 | Seagen, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 270 | Section 10a, Horizon Therapeutics Public Ltd Co reciprocity | DEF 14A | — | 0001193125-23-180318 | Horizon Therapeutics Public Ltd Co's most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 271 | Section 10a, Penumbra, Inc. reciprocity | DEF 14A | — | 0001321732-26-000010 | Penumbra, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 272 | Section 10a, Quidel Corporation reciprocity | DEF 14A | — | 0001906324-26-000018 | Quidel Corporation names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 273 | Section 10a, 10x Genomics, Inc. reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 274 | Section 10a, Agilent Technologies, Inc. reciprocity | DEF 14A | — | 0001193125-26-040286 | Agilent Technologies, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 275 | Section 10a, Bio-Techne Corporation reciprocity | DEF 14A | — | 0001308179-25-000599 | Bio-Techne Corporation names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 276 | Section 10a, Guardant Health, Inc. reciprocity | DEF 14A | — | 0001193125-26-187403 | Guardant Health, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 277 | Section 10a, DexCom, Inc. reciprocity | DEF 14A | — | 0001093557-26-000061 | DexCom, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 278 | Section 10a, Hologic, Inc. reciprocity | DEF 14A | — | 0001140361-25-001287 | Hologic, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 279 | Section 10a, IDEXX Laboratories, Inc. reciprocity | DEF 14A | — | 0000874716-26-000064 | IDEXX Laboratories, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 280 | Section 10a, Insulet Corporation reciprocity | DEF 14A | — | 0001140361-26-013333 | Insulet Corporation names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 281 | Section 10a, Alnylam Pharmaceuticals, Inc. reciprocity | DEF 14A | — | 0001628280-26-023923 | Alnylam Pharmaceuticals, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 282 | Section 10a, BioMarin Pharmaceutical Inc. reciprocity | DEF 14A | — | 0001628280-26-026290 | BioMarin Pharmaceutical Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 283 | Section 10a, Natera, Inc. reciprocity | DEF 14A | — | 0001104659-26-047770 | Natera, Inc. names Exact Sciences in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 284 | Section 10a, Align Technology, Inc. reciprocity | DEF 14A | — | 0001097149-26-000023 | Align Technology, Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 285 | Section 10a, Masimo Corporation reciprocity | DEF 14A | — | 0001104659-26-054180 | Masimo Corporation's most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
| 286 | Section 10a, ResMed Inc. reciprocity | DEF 14A | — | 0000943819-26-000080 | ResMed Inc.'s most recent proxy was read; its disclosed peer group does not include Exact Sciences. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.